Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...

Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.

Researchers from Moffitt Cancer Center have found a new way to boost cancer immunotherapy by targeting a protein called ...

Researchers have discovered a strong association between the use of immune checkpoint inhibitors for cancer treatment and a ...

Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...

More than a decade after Merck’s Keytruda and BMS’ Yervoy ushered in the immuno-oncology revolution, the space is at a ...

The findings appeared March 13, 2025 in Cancer Cell. HNSCCs occur in the oral ... protein was a good marker for some people while the CTLA-4 protein was a good marker for others," Ferris said.

This hampers the effects of existing immunotherapies like CTLA-4 and PD-1 inhibitors, which work by mobilizing a person’s own immune system against their cancer. As a result, people with cold ...

Additional Phase 2 data for vilastobart, a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab in ...

Agenus is a leading immuno-oncology company targeting cancer with a comprehensive pipeline ... is a human Fc enhanced CTLA-4 blocking antibody designed to boost both innate and adaptive anti ...

SAN DIEGO and SUZHOU, China, March 13, 2025 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today ...

In November 2024, CStone presented preclinical data for CS2009 at the 39th SITC Annual Meeting. These results show that CS2009 exhibits superior anti-tumor activity compared to potential competitors, ...